322 related articles for article (PubMed ID: 27065330)
1. Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline.
Liu PP; Liu J; Jiang WQ; Carew JS; Ogasawara MA; Pelicano H; Croce CM; Estrov Z; Xu RH; Keating MJ; Huang P
Oncogene; 2016 Oct; 35(43):5663-5673. PubMed ID: 27065330
[TBL] [Abstract][Full Text] [Related]
2. Effective elimination of chronic lymphocytic leukemia cells in the stromal microenvironment by a novel drug combination strategy using redox-mediated mechanisms.
Zhang W; Pelicano H; Yin R; Zeng J; Wen T; Ding L; Huang R
Mol Med Rep; 2015 Nov; 12(5):7374-88. PubMed ID: 26458979
[TBL] [Abstract][Full Text] [Related]
3. The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells.
Vangapandu HV; Ayres ML; Bristow CA; Wierda WG; Keating MJ; Balakrishnan K; Stellrecht CM; Gandhi V
Neoplasia; 2017 Oct; 19(10):762-771. PubMed ID: 28863345
[TBL] [Abstract][Full Text] [Related]
4. The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine.
Crassini K; Stevenson WS; Mulligan SP; Best OG
Leuk Lymphoma; 2015; 56(12):3407-17. PubMed ID: 25804768
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
[TBL] [Abstract][Full Text] [Related]
6. Targeting p53-deficient chronic lymphocytic leukemia cells in vitro and in vivo by ROS-mediated mechanism.
Liu J; Chen G; Pelicano H; Liao J; Huang J; Feng L; Keating MJ; Huang P
Oncotarget; 2016 Nov; 7(44):71378-71389. PubMed ID: 27655686
[TBL] [Abstract][Full Text] [Related]
7. Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4
Brown ZJ; Fu Q; Ma C; Kruhlak M; Zhang H; Luo J; Heinrich B; Yu SJ; Zhang Q; Wilson A; Shi ZD; Swenson R; Greten TF
Cell Death Dis; 2018 May; 9(6):620. PubMed ID: 29795111
[TBL] [Abstract][Full Text] [Related]
8. Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart.
Kennedy JA; Kiosoglous AJ; Murphy GA; Pelle MA; Horowitz JD
J Cardiovasc Pharmacol; 2000 Dec; 36(6):794-801. PubMed ID: 11117381
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone.
Kennedy JA; Unger SA; Horowitz JD
Biochem Pharmacol; 1996 Jul; 52(2):273-80. PubMed ID: 8694852
[TBL] [Abstract][Full Text] [Related]
10. Protein kinase C-β-dependent changes in the glucose metabolism of bone marrow stromal cells of chronic lymphocytic leukemia.
von Heydebrand F; Fuchs M; Kunz M; Voelkl S; Kremer AN; Oostendorp RAJ; Wilke J; Leitges M; Egle A; Mackensen A; Lutzny-Geier G
Stem Cells; 2021 Jun; 39(6):819-830. PubMed ID: 33539629
[TBL] [Abstract][Full Text] [Related]
11. Modeling the chronic lymphocytic leukemia microenvironment in vitro.
Crassini K; Shen Y; Mulligan S; Giles Best O
Leuk Lymphoma; 2017 Feb; 58(2):266-279. PubMed ID: 27756161
[TBL] [Abstract][Full Text] [Related]
12. Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1-derived peptides overcomes drug resistance.
Pramil E; Herbi Bastian L; Denèfle T; Nemati F; Xiao M; Lardé E; Maloum K; Roos-Weil D; Chapiro E; Le Garff-Tavernier M; Davi F; Decaudin D; Sarfati M; Nguyen-Khac F; Merle-Béral H; Karoyan P; Susin SA
Blood Adv; 2019 Oct; 3(20):2920-2933. PubMed ID: 31648314
[TBL] [Abstract][Full Text] [Related]
13. In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts.
Mollinedo F; de la Iglesia-Vicente J; Gajate C; Estella-Hermoso de Mendoza A; Villa-Pulgarin JA; de Frias M; Roué G; Gil J; Colomer D; Campanero MA; Blanco-Prieto MJ
Clin Cancer Res; 2010 Apr; 16(7):2046-54. PubMed ID: 20233887
[TBL] [Abstract][Full Text] [Related]
14. Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target.
Hegde GV; Peterson KJ; Emanuel K; Mittal AK; Joshi AD; Dickinson JD; Kollessery GJ; Bociek RG; Bierman P; Vose JM; Weisenburger DD; Joshi SS
Mol Cancer Res; 2008 Dec; 6(12):1928-36. PubMed ID: 19074837
[TBL] [Abstract][Full Text] [Related]
15. Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism.
Trachootham D; Zhang H; Zhang W; Feng L; Du M; Zhou Y; Chen Z; Pelicano H; Plunkett W; Wierda WG; Keating MJ; Huang P
Blood; 2008 Sep; 112(5):1912-22. PubMed ID: 18574029
[TBL] [Abstract][Full Text] [Related]
16. Dissociation between metabolic and efficiency effects of perhexiline in normoxic rat myocardium.
Unger SA; Kennedy JA; McFadden-Lewis K; Minerds K; Murphy GA; Horowitz JD
J Cardiovasc Pharmacol; 2005 Dec; 46(6):849-55. PubMed ID: 16306812
[TBL] [Abstract][Full Text] [Related]
17. Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor.
Vaisitti T; Gaudino F; Ouk S; Moscvin M; Vitale N; Serra S; Arruga F; Zakrzewski JL; Liou HC; Allan JN; Furman RR; Deaglio S
Haematologica; 2017 Nov; 102(11):1878-1889. PubMed ID: 28860341
[TBL] [Abstract][Full Text] [Related]
18. Adhesion of ZAP-70+ chronic lymphocytic leukemia cells to stromal cells is enhanced by cytokines and blocked by inhibitors of the PI3-kinase pathway.
Lafarge ST; Johnston JB; Gibson SB; Marshall AJ
Leuk Res; 2014 Jan; 38(1):109-15. PubMed ID: 23981382
[TBL] [Abstract][Full Text] [Related]
19. The potential anticancer agent PK11195 induces apoptosis irrespective of p53 and ATM status in chronic lymphocytic leukemia cells.
Santidrián AF; Cosialls AM; Coll-Mulet L; Iglesias-Serret D; de Frias M; González-Gironès DM; Campàs C; Domingo A; Pons G; Gil J
Haematologica; 2007 Dec; 92(12):1631-8. PubMed ID: 18055986
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
